Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Intra-DRG list updated in France

Certain medical devices are financed within the DRG tariff but require explicit review of clinical evidence by the National Commission for the Evaluation of Medical Devices and Health Technologies CNEDiMTS to ensure that they are safe and effective. This mechanism is called “intra-DRG (intra-GHS) coverage”. The mechanism is applicable to particularly invasive devices. Only devices listed in the intra-DRG list can be purchased by hospitals. 

On April 8, 2024, the updated version of the intra-DRG list of April 6, 2024, was published. Changes concerned Title I, “Cardiac and vascular implants”. 

One new device was registered: 

  • Implantable cardiac defibrillator with retrosternal probe AURORA EV ICD MRI SURESCAN by Medtronic.

Other changes concerned modifying the registration conditions and renewing registration or extending the registration. Below are some examples:

  • Thrombo-aspiration catheters PENUMBRA (PENUMBRA ACE 60, PENUMBRA ACE 68, PENUMBRA 3MAXC, PENUMBRA JET7, PENUMBRA JET D, and PENUMBRA RED) by Penumbra: renewal and modification of registration conditions;
  • Balloon guide catheters MERCI and FLOWGATE2 by Stryker: modification of registration conditions and renewal.

More details can be found in French here

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.